New DNA sequencer put to the test against gold standard in cancer genetics
NCT ID NCT07160010
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 35 times
Summary
This study will check if a newer, cheaper DNA sequencing machine (MGI) gives the same results as the current standard (Illumina) when testing for genetic changes linked to breast, ovarian, and other cancers. Researchers will use leftover DNA samples from 248 patients who already had genetic testing. The goal is to see if the MGI platform is a reliable alternative for diagnosing hereditary conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.